Immunotherapy, a rapidly evolving field in oncology, has revolutionized the treatment landscape for several malignancies. Harnessing the body's immune system to fight cancer, it provides a promising alternative to traditional therapies. However, the complexity of the immune system and the diverse mechanisms of action of different immunotherapies pose significant challenges for physicians.
The immune system is a complex network of cells, tissues, and organs that work together to defend the body against harmful invaders. At the heart of this system are T cells, which are capable of recognizing and destroying cancer cells. However, cancer cells can evade these defenses by exploiting immune checkpoints, proteins that normally prevent T cells from attacking healthy cells.
Immunotherapies can be broadly classified into two categories: active and passive. Active immunotherapies, such as cancer vaccines, stimulate the patient's own immune system to attack cancer cells. Passive immunotherapies, such as monoclonal antibodies and adoptive cell therapies, involve the administration of immune system components to enhance the body's anti-cancer response.
Immune checkpoint inhibitors are a type of immunotherapy that block immune checkpoints, thereby allowing T cells to attack cancer cells. These drugs have shown remarkable efficacy in several types of cancer, including melanoma, lung cancer, and kidney cancer. However, they can also cause immune-related adverse events, which require careful management.
Despite the success of immunotherapies, many patients do not respond to these treatments. Ongoing research is focused on identifying biomarkers to predict response, developing combination therapies, and exploring new immune targets.
Immunotherapy represents a paradigm shift in cancer treatment, offering hope to patients who have exhausted other options. As our understanding of the immune system and cancer biology continues to grow, so too will the potential of immunotherapy to improve patient outcomes. Physicians must stay abreast of this rapidly evolving field to provide the best possible care to their patients.
1.
A new way to measure suicide risk?
2.
3D virtual staining technology enables non-invasive observation of cancer tissue
3.
Perioperative Nivolumab Boosts EFS Versus Neoadjuvant-Only Nivolumab in NSCLC
4.
I Understand Why Defense Secretary Austin Kept His Prostate Cancer Quiet.
5.
ASCO: Vepdegestrant ups survival in ER+, HER2− advanced breast cancer with ESR1 mutations
1.
Hemophilia B and Gene Therapy: A New Chapter with Etranacogene Dezaparvovec
2.
Driving Impact: Oncology Pharmaceutical Marketing Strategies in the USA
3.
7 Subtle Signs of Leukemia: How to Spot the Symptoms Early
4.
Predicting Incidental Prostate Cancer in BPH Surgery Patients
5.
How Should We Approach Solid Pseudopapillary Neoplasm of the Pancreas with Hepatic Metastases?
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part V
2.
The Comprehensive Impact of CDK4/6 Inhibition in HR+/HER2- Metastatic Breast Cancer: Insights from PALOMA-2.
3.
Current Scenario of Cancer- Q&A Session to Close the Gap Part II
4.
Unmet Needs in ALK Positive NSCLC- The Challenges in the Current Care
5.
Navigating the Complexities of Ph Negative ALL - Part IX
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation